{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T00:08:08Z","timestamp":1791331688886,"version":"4.3.1"},"reference-count":58,"publisher":"MDPI AG","issue":"2","license":[{"start":{"date-parts":[[2025,2,7]],"date-time":"2025-02-07T00:00:00Z","timestamp":1738886400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Microorganisms"],"abstract":"<jats:p>Acinetobacter baumannii complex (ABC) can result in a panoply of severe syndromes, including pneumonia and septic shock. Options available for treating infections caused by ABC and, more importantly, by carbapenem-resistant ABC (CRAB) are limited because of the increasing prevalence of antimicrobial resistance. Furthermore, many older agents, such as polymyxin and colistin, have limited lung penetration and are associated with significant toxicities. These factors underscore the urgent need for new paradigms to address ABC and CRAB. Two agents, cefiderocol and sulbactam-durlobactam, are now available to treat CRAB infections. In addition, several anti-infectives that target CRAB are in later-stage clinical trials. In order to place these newer molecules in context and to help clinicians appreciate the emerging potential drug development pipeline, we describe the in vitro activity, mechanisms of action, and clinical trial data not only for the commercially now available alternatives, such as cefiderocol and sulbactam-durlobactam, but also review these topics for molecules undergoing phase II and III clinical trials. Specifically, we discuss and analyze data related to four novel drugs from ABC: BV-100, cefepime-zidebactam, zosurabalpin, and OMN6.<\/jats:p>","DOI":"10.3390\/microorganisms13020356","type":"journal-article","created":{"date-parts":[[2025,2,7]],"date-time":"2025-02-07T05:04:33Z","timestamp":1738904673000},"page":"356","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":20,"title":["Acinetobacter baumannii Complex Infections: New Treatment Options in the Antibiotic Pipeline"],"prefix":"10.3390","volume":"13","author":[{"given":"Noayna","family":"Arshad","sequence":"first","affiliation":[{"name":"Department of Medicine, Medstar Washington Hospital Center, Washington, DC 20010, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wael","family":"Azzam","sequence":"additional","affiliation":[{"name":"Department of Medicine, Medstar Washington Hospital Center, Washington, DC 20010, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marya D.","family":"Zilberberg","sequence":"additional","affiliation":[{"name":"EviMed Research Group, LLC, Goshen, MA 01032, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4537-8328","authenticated-orcid":false,"given":"Andrew F.","family":"Shorr","sequence":"additional","affiliation":[{"name":"Pulmonary and Critical Care Medicine, Medstar Washington Hospital Center, Washington, DC 20010, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,2,7]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"100902","DOI":"10.1016\/S2666-5247(24)00134-4","article-title":"WHO global research priorities for antimicrobial resistance in human health","volume":"5","author":"Bertagnolio","year":"2024","journal-title":"Lancet Microbe"},{"key":"ref_2","doi-asserted-by":"crossref","unstructured":"Br\u00fcssow, H. (2024). The antibiotic resistance crisis and the development of new antibiotics. Microb. Biotechnol., 17.","DOI":"10.1111\/1751-7915.14510"},{"key":"ref_3","unstructured":"(2024, December 03). Available online: https:\/\/www.cdc.gov\/antimicrobial-resistance\/data-research\/threats\/index.html."},{"key":"ref_4","unstructured":"(2024, December 03). Available online: https:\/\/www.who.int\/publications\/i\/item\/9789240093461."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"S179","DOI":"10.1093\/cid\/ciad094","article-title":"Navigating Available Treatment Options for Carbapenem-Resistant Acinetobacter baumannii-calcoaceticus Complex Infections","volume":"76","author":"Shields","year":"2023","journal-title":"Clin. Infect. Dis."},{"key":"ref_6","doi-asserted-by":"crossref","unstructured":"Grygiel, I., Bajrak, O., W\u00f3jcicki, M., Krusiec, K., Jo\u0144czyk-Matysiak, E., G\u00f3rski, A., Majewska, J., and Letkiewicz, S. (2024). Comprehensive Approaches to Combatting Acinetobacter baumannii Biofilms: From Biofilm Structure to Phage-Based Therapies. Antibiotics, 13.","DOI":"10.3390\/antibiotics13111064"},{"key":"ref_7","doi-asserted-by":"crossref","unstructured":"Novovi\u0107, K., and Jov\u010di\u0107, B. (2023). Colistin Resistance in Acinetobacter baumannii: Molecular Mechanisms and Epidemiology. Antibiotics, 12.","DOI":"10.3390\/antibiotics12030516"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.2147\/IDR.S253440","article-title":"Survey on genetic diversity, biofilm formation, and detection of colistin resistance genes in clinical isolates of Acinetobacter baumannii","volume":"13","author":"Khoshnood","year":"2020","journal-title":"Infect. Drug Resist."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1747","DOI":"10.1080\/22221751.2019.1698273","article-title":"The incidence and prevalence of hospital-acquired (carbapenem-resistant) Acinetobacter baumannii in Europe, Eastern Mediterranean and Africa: A systematic review and meta-analysis","volume":"8","author":"Ayobami","year":"2019","journal-title":"Emerg. Microbes Infect."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1017\/ice.2018.58","article-title":"A Systematic Review of the Burden of Multidrug-Resistant Healthcare-Associated Infections Among Intensive Care Unit Patients in Southeast Asia: The Rise of Multidrug-Resistant Acinetobacter baumannii","volume":"39","author":"Teerawattanapong","year":"2018","journal-title":"Infect. Control. Hosp. Epidemiol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1016\/j.ajic.2024.04.184","article-title":"Carbapenem-resistant Acinetobacter baumannii complex in the United States-An epidemiological and molecular description of isolates collected through the Emerging Infections Program, 2019","volume":"52","author":"Bulens","year":"2024","journal-title":"Am. J. Infect. Control."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1016\/j.chest.2018.12.024","article-title":"A Novel Algorithm to Analyze Epidemiology and Outcomes of Carbapenem Resistance Among Patients With Hospital-Acquired and Ventilator-Associated Pneumonia: A Retrospective Cohort Study","volume":"155","author":"Zilberberg","year":"2019","journal-title":"Chest"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"220119","DOI":"10.1183\/16000617.0119-2022","article-title":"New antibiotics for Gram-negative pneumonia","volume":"31","author":"Bassetti","year":"2022","journal-title":"Eur. Respir. Rev."},{"key":"ref_14","doi-asserted-by":"crossref","unstructured":"Karakonstantis, S., Rousaki, M., and Kritsotakis, E.I. (2022). Cefiderocol: Systematic Review of Mechanisms of Resistance, Heteroresistance and In Vivo Emergence of Resistance. Antibiotics, 11.","DOI":"10.3390\/antibiotics11060723"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1038\/s41429-024-00762-y","article-title":"In vitro resistance development gives insights into molecular resistance mechanisms against cefiderocol","volume":"77","author":"Kriz","year":"2024","journal-title":"J. Antibiot."},{"key":"ref_16","doi-asserted-by":"crossref","unstructured":"Kimbrough, J.H., Maher, J.M., Sader, H.S., Castanheira, M., and Mendes, R.E. (2024). In vitro activity assessment of cefiderocol against Enterobacterales, Pseudomonas aeruginosa, and Acinetobacter spp., including \u03b2-lactam nonsusceptible molecularly characterized isolates, collected from 2020 to 2021 in the United States and European hospitals. Microbiol Spectr., 12.","DOI":"10.1128\/spectrum.01474-24"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/S1473-3099(20)30731-3","article-title":"Cefiderocol versus high-dose, extended-infusion meropenem for the treatment of Gram-negative nosocomial pneumonia (APEKS-NP): A randomised, double-blind, phase 3, non-inferiority trial","volume":"21","author":"Wunderink","year":"2021","journal-title":"Lancet Infect Dis."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1016\/S1473-3099(20)30796-9","article-title":"Efficacy and safety of cefiderocol or best available therapy for the treatment of serious infections caused by carbapenem-resistant Gram-negative bacteria (CREDIBLE-CR): A randomised, open-label, multicentre, pathogen-focused, descriptive, phase 3 trial","volume":"21","author":"Bassetti","year":"2021","journal-title":"Lancet Infect Dis."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1080\/14787210.2022.2071701","article-title":"Treatment of carbapenem-resistant Pseudomonas aeruginosa infections: A case for cefiderocol","volume":"20","author":"Canton","year":"2022","journal-title":"Expert Rev. Anti-Infect. Ther."},{"key":"ref_20","doi-asserted-by":"crossref","unstructured":"Sansone, P., Giaccari, L.G., Coppolino, F., Aurilio, C., Barbarisi, A., Passavanti, M.B., Pota, V., and Pace, M.C. (2022). Cefiderocol for Carbapenem-Resistant Bacteria: Handle with Care! A Review of the Real-World Evidence. Antibiotics, 11.","DOI":"10.3390\/antibiotics11070904"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"2752","DOI":"10.1093\/jac\/dkad298","article-title":"Cefiderocol use for the treatment of infections by carbapenem-resistant Gram-negative bacteria: An Italian multicentre real-life experience","volume":"78","author":"Piccica","year":"2023","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.1007\/s40121-024-01016-y","article-title":"Use of Cefiderocol in Adult Patients: Descriptive Analysis from a Prospective, Multicenter, Cohort Study","volume":"13","author":"Giacobbe","year":"2024","journal-title":"Infect Dis. Ther."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"4427","DOI":"10.2147\/IDR.S475462","article-title":"Effectiveness and Safety of Cefiderocol in Clinical Practice for Treatment of Patients with Gram-Negative Bacterial Infections: US Interim Results of the PROVE Study","volume":"17","author":"Clancy","year":"2024","journal-title":"Infect Drug Resist."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"e0214221","DOI":"10.1128\/aac.02142-21","article-title":"Cefiderocol- Compared to Colistin-Based Regimens for the Treatment of Severe Infections Caused by Carbapenem-Resistant Acinetobacter baumannii","volume":"66","author":"Falcone","year":"2022","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_25","doi-asserted-by":"crossref","unstructured":"Mazzitelli, M., Gregori, D., Sasset, L., Trevenzoli, M., Scaglione, V., Lo Menzo, S., Marinello, S., Mengato, D., Venturini, F., and Tiberio, I. (2023). Cefiderocol-Based versus Colistin-Based Regimens for Severe Carbapenem-Resistant Acinetobacter baumannii Infections: A Propensity Score-Weighted, Retrospective Cohort Study during the First Two Years of the COVID-19 Pandemic. Microorganisms, 11.","DOI":"10.3390\/microorganisms11040984"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"107047","DOI":"10.1016\/j.ijantimicag.2023.107047","article-title":"Clinical efficacy of cefiderocol-based regimens in patients with carbapenem-resistant Acinetobacter baumannii infections: A systematic review with meta-analysis","volume":"63","author":"Gatti","year":"2024","journal-title":"Int. J. Antimicrob. Agents"},{"key":"ref_27","doi-asserted-by":"crossref","unstructured":"Tamma, P.D., Heil, E.L., Justo, J.A., Mathers, A.J., Satlin, M.J., and Bonomo, R.A. (2024). Infectious Diseases Society of America 2024 Guidance on the Treatment of Antimicrobial-Resistant Gram-Negative Infections. Clin. Infect. Dis., ciae403.","DOI":"10.1093\/cid\/ciae403"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1016\/j.cmi.2021.11.025","article-title":"European Society of Clinical Microbiology and Infectious Diseases (ESCMID) guidelines for the treatment of infections caused by multidrug-resistant Gram-negative bacilli (endorsed by European society of intensive care medicine)","volume":"28","author":"Paul","year":"2022","journal-title":"Clin. Microbiol. Infect."},{"key":"ref_29","doi-asserted-by":"crossref","unstructured":"Shapiro, A.B.C., Moussa, S.H., McLeod, S.M., Durand-R\u00e9ville, T., and Miller, A.A. (2021). Durlobactam, a New Diazabicyclooctane \u03b2-Lactamase Inhibitor for the Treatment of Acinetobacter Infections in Combination With Sulbactam. Front. Microbiol., 12.","DOI":"10.3389\/fmicb.2021.709974"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"2616","DOI":"10.1093\/jac\/dkaa208","article-title":"In vitro activity of sulbactam\/durlobactam against global isolates of carbapenem-resistant Acinetobacter baumannii","volume":"75","author":"Seifert","year":"2020","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"e0078122","DOI":"10.1128\/aac.00781-22","article-title":"In Vitro Activity of Sulbactam-Durlobactam against Global Isolates of Acinetobacter baumannii-calcoaceticus Complex Collected from 2016 to 2021","volume":"66","author":"Karlowsky","year":"2022","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_32","doi-asserted-by":"crossref","unstructured":"Principe, L., Di Bella, S., Conti, J., Perilli, M., Piccirilli, A., Mussini, C., and Decorti, G. (2022). Acinetobacter baumannii Resistance to Sulbactam\/Durlobactam: A Systematic Review. Antibiotics, 11.","DOI":"10.3390\/antibiotics11121793"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"S202","DOI":"10.1093\/cid\/ciad096","article-title":"The Pharmacokinetics\/Pharmacodynamic Relationship of Durlobactam in Combination With Sulbactam in In Vitro and In Vivo Infection Model Systems Versus Acinetobacter baumannii-calcoaceticus Complex","volume":"76","author":"Bhavnani","year":"2023","journal-title":"Clin. Infect. Dis."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.1016\/S1473-3099(23)00184-6","article-title":"Efficacy and safety of sulbactam-durlobactam versus colistin for the treatment of patients with serious infections caused by Acinetobacter baumannii-calcoaceticus complex: A multicentre, randomised, active-controlled, phase 3, non-inferiority clinical trial (ATTACK)","volume":"23","author":"Kaye","year":"2023","journal-title":"Lancet Infect. Dis."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"ofae140","DOI":"10.1093\/ofid\/ofae140","article-title":"Clinical Outcomes for Patients with Monomicrobial vs. Polymicrobial Acinetobacter baumannii-calcoaceticus Complex Infections Treated With Sulbactam-Durlobactam or Colistin: A Subset Analysis From a Phase 3 Clinical Trial","volume":"11","author":"McLeod","year":"2024","journal-title":"Open Forum Infect. Dis."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"dlad078","DOI":"10.1093\/jacamr\/dlad078","article-title":"Salvage therapy with sulbactam\/durlobactam against cefiderocol-resistant Acinetobacter baumannii in a critically ill burn patient: Clinical challenges and molecular characterization","volume":"5","author":"Tiseo","year":"2023","journal-title":"JAC Antimicrob. Resist."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"ofad504","DOI":"10.1093\/ofid\/ofad504","article-title":"In Vivo Emergence of Pandrug-Resistant Acinetobacter baumannii Strain: Comprehensive Resistance Characterization and Compassionate Use of Sulbactam-Durlobactam","volume":"10","author":"VanNatta","year":"2023","journal-title":"Open Forum Infect. Dis."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"2099","DOI":"10.1016\/j.drudis.2021.07.001","article-title":"Rifabutin for infusion (BV100) for the treatment of severe carbapenem-resistant Acinetobacter baumannii infections","volume":"26","author":"Trebosc","year":"2021","journal-title":"Drug Discov. Today"},{"key":"ref_39","doi-asserted-by":"crossref","unstructured":"Kyriakidis, I., Vasileiou, E., Pana, Z.D., and Tragiannidis, A. (2021). Acinetobacter baumannii Antibiotic Resistance Mechanisms. Pathogens, 10.","DOI":"10.3390\/pathogens10030373"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1038\/s41564-020-0737-6","article-title":"A nutrient-limited screen unmasks rifabutin hyperactivity for extensively drug-resistant Acinetobacter baumannii","volume":"5","author":"Luna","year":"2020","journal-title":"Nat. Microbiol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"3552","DOI":"10.1093\/jac\/dkaa370","article-title":"In vitro activity of rifabutin against 293 contemporary carbapenem-resistant Acinetobacter baumannii clinical isolates and characterization of rifabutin mode of action and resistance mechanisms","volume":"75","author":"Trebosc","year":"2020","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_42","unstructured":"(2024, December 22). Available online: https:\/\/www.bioversys.com\/bioversys-announces-first-patient-dosed-in-phase-2-clinical-trial-with-bv100."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"e00115","DOI":"10.1128\/CMR.00115-20","article-title":"New \u03b2-Lactam-\u03b2-Lactamase inhibitor combinations","volume":"34","author":"Yahav","year":"2020","journal-title":"Clin. Microbiol. Rev."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"e01238-17","DOI":"10.1128\/AAC.01238-17","article-title":"Potent \u03b2-Lactam enhancer activity of zidebactam and WCK 5153 against Acinetobacter baumannii, including carbapenemase-producing clinical isolates","volume":"61","author":"Moya","year":"2018","journal-title":"Antimicrob. Agents Chemother"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"e00948-18","DOI":"10.1128\/AAC.00948-18","article-title":"Assessment of the in vivo efficacy of WCK 5222 (cefepime-zidebactam) against carbapenem-resistant Acinetobacter baumannii in the neutropenic murine lung infection model","volume":"62","author":"Avery","year":"2018","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"2642","DOI":"10.1093\/jac\/dkac233","article-title":"Antimicrobial activity of cefepime\/zidebactam (WCK 5222), a \u03b2-lactam\/\u03b2-lactam enhancer combination, against clinical isolates of Gram-negative bacteria collected worldwide (2018\u20132019)","volume":"77","author":"Sader","year":"2022","journal-title":"J. Antimicrob. Chemother"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"2938","DOI":"10.1093\/jac\/dkz294","article-title":"Activity of cefepime\/zidebactam (WCK 5222) against Enterobacteriaceae, Pseudomonas aeruginosa and Acinetobacter baumannii endemic to New York City medical centres","volume":"74","author":"Khan","year":"2019","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_48","doi-asserted-by":"crossref","unstructured":"Cedano, J., Baez, M., Pasteran, F., Monta\u00f1a, S.D., Ra, G., Fua, V., Corso, A., Tolmasky, M.E., Bonomo, R.A., and Ram\u00edrez, M.S. (2022). Zidebactam restores sulbactam susceptibility against carbapenem-resistant Acinetobacter baumannii isolates. Front. Cell. Infect. Microbiol., 12.","DOI":"10.3389\/fcimb.2022.918868"},{"key":"ref_49","unstructured":"(2024, December 22). Available online: https:\/\/www.expresspharma.in\/us-body-clinical-and-laboratory-standards-institute-clsi-awards-high-susceptibility-breakpoints-to-zaynich-zidebactam-cefepime-wck-5222\/."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1038\/s41586-023-06873-0","article-title":"A novel antibiotic class targeting the lipopolysaccharide transporter","volume":"625","author":"Zampaloni","year":"2024","journal-title":"Nature"},{"key":"ref_51","unstructured":"Hawser, S., Kothari, N., Valmont, T., Louvel, S., and Zampaloni, C. (2024, January 27\u201330). MIC Distributions and Activity of the Novel Anti-Acinetobacter Agent Zosurabalpin (RG6006). Proceedings of the ECCMID 2024, Barcelona, Spain."},{"key":"ref_52","unstructured":"Shortridge, D., Rhomberg, P., Huband, M., Castanheira, M., Louvel, S., and Zampaloni, C. (2023, January 15\u201318). In Vitro Activity of Novel Compound RG6006 against Clinical Isolates of Acinetobacter Baumannii-calcoaceticus Complex in the Presence of 20% Human Serum. Proceedings of the ECCMID 2023, Copenhagen, Denmark."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"ofad500.1749","DOI":"10.1093\/ofid\/ofad500.1749","article-title":"Safety, tolerability, and pharmacokinetics (PK) in healthy participants following single dose administration of zosurabalpin, a novel pathogen-specific antibiotic for the treatment of serious Acinetobacter infections","volume":"10","author":"Guenther","year":"2023","journal-title":"Open Forum Infect. Dis."},{"key":"ref_54","unstructured":"Sabatini, D., Erbetti, I., Louvel, S., Felici, A., and Zampaloni, C. (2024, January 27\u201330). Assessment of Zosurabalpin Activity in Combination with Other Antibiotics. Proceedings of the ECCMID 2024, Barcelona, Spain."},{"key":"ref_55","doi-asserted-by":"crossref","unstructured":"Mandel, S., Michaeli, J., Nur, N., Erbetti, I., Zazoun, J., Ferrari, L., Felici, A., Cohen-Kutner, M., and Bachnoff, N. (2022). OMN6: A novel bioengineered peptide for treatment of multidrug resistant Gram negative bacteria. Sci. Rep., 11.","DOI":"10.1038\/s41598-021-86155-9"},{"key":"ref_56","doi-asserted-by":"crossref","unstructured":"Rangel, K., Lechuga, G.C., Provance DWJr Morel, C.M., and De Simone, S.G. (2023). An Update on the Therapeutic Potential of Antimicrobial Peptides against Acinetobacter baumannii Infections. Pharmaceuticals, 16.","DOI":"10.20944\/preprints202307.0770.v1"},{"key":"ref_57","doi-asserted-by":"crossref","unstructured":"Michaeli, J., Mandel, S., Maximov, S., Zazoun, J., Savoia, P., Kothari, N., Valmont, T., Ferrari, L., Duncan, L.R., and Hawser, S. (2022). In vitro and in vivo antimicrobial activity of the novel peptide OMN6 against multidrug-resistant Acinetobacter baumannii. Antibiotics, 11.","DOI":"10.3390\/antibiotics11091201"},{"key":"ref_58","unstructured":"(2024, December 25). Available online: https:\/\/omnixmedical.com\/2024\/05\/10\/safety_and_pharmacokinetic_results_from_the_first_in_human_study\/."}],"container-title":["Microorganisms"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2076-2607\/13\/2\/356\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T16:28:27Z","timestamp":1760027307000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2076-2607\/13\/2\/356"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,7]]},"references-count":58,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2025,2]]}},"alternative-id":["microorganisms13020356"],"URL":"https:\/\/doi.org\/10.3390\/microorganisms13020356","relation":{},"ISSN":["2076-2607"],"issn-type":[{"value":"2076-2607","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,7]]}}}